Mergers & Acquisitions
Ciphergen stockholders approve sale of proteomics instrument business to Bio-Rad Laboratories
Published in Biotech Business Week, November 27th, 2006
Bio-Rad will purchase this business for approximately $20 million in cash. In addition, Bio-Rad will make a $3 million equity investment in Ciphergen. Ciphergen expects to close the transaction on or before November 1, 2006.
"With the approval of the sale of the instrument business, Ciphergen completes its transition into a specialty diagnostics company and is well-positioned to bring high-value molecular diagnostics to physicians and their patients," said Gail S. Page,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
More Articles from Biotech Business Week
- Healthcare Costs
Principal Financial Group survey shows rising healthcare costs hurting household savings - Market Analysis
More consumer-direct fall enrollment options seen for employees but employers cool to plans - Market Analysis
Worldwide catheter market is poised for growth - Mergers & Acquisitions
Merck & Co. to acquire RNA developer Sirna Therapeutics in deal worth $1.1 billion - Pharmacology
Studies from Cornell University, Institute for Computational Biomedicine in the area of pharmacology published - Acromegaly
Ambrilia reports positive results from study of prolonged release formulation of Octreotide - More from this issue of Biotech Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
